Kiniksa Pharmaceuticals, Ltd. (KNSA) 의 후행 P/E는 58.0, 선행 P/E 37.7. 후행 이익수익률은 1.72%, 선행 이익수익률 2.65%. PEG 0.61 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $11.70.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 69/100 2/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | -26.4 | 0.00 | -24.57 | 0.00 | - |
| 2017 | -9.7 | -0.06 | -7.05 | 0.00 | - |
| 2018 | -8.0 | -0.11 | -4.27 | 0.00 | - |
| 2019 | -3.7 | 0.26 | 2.65 | 0.00 | - |
| 2020 | -6.8 | 0.53 | 3.50 | 0.00 | - |
| 2021 | -5.1 | 0.43 | 4.36 | 20.94 | - |
| 2022 | 5.7 | -0.03 | 2.62 | 4.72 | - |
| 2023 | 87.3 | -0.94 | 2.80 | 4.55 | - |
| 2024 | -32.7 | 0.08 | 3.22 | 3.34 | - |
| 2025 | 51.9 | -0.22 | 5.39 | 4.52 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $-0.74 | $0.00 | $-23.97M | - |
| 2017 | $-2.00 | $0.00 | $-64.87M | - |
| 2018 | $-3.49 | $0.00 | $-103.23M | - |
| 2019 | $-2.99 | $0.00 | $-161.87M | - |
| 2020 | $-2.61 | $0.00 | $-161.38M | - |
| 2021 | $-2.30 | $38.54M | $-157.92M | -409.7% |
| 2022 | $2.60 | $220.18M | $183.36M | 83.3% |
| 2023 | $0.20 | $270.26M | $14.08M | 5.2% |
| 2024 | $-0.60 | $423.24M | $-43.19M | -10.2% |
| 2025 | $0.75 | $677.56M | $59.01M | 8.7% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $1.22 | $1.02 – $1.45 | $914.11M | $913.72M – $914.49M | 5 |
| 2027 | $1.61 | $1.17 – $1.89 | $1.08B | $1.05B – $1.1B | 5 |
| 2028 | $2.26 | $1.28 – $3.00 | $1.24B | $1.24B – $1.24B | 6 |
| 2029 | $2.80 | $2.74 – $2.87 | $1.35B | $1.33B – $1.38B | 4 |
| 2030 | $4.42 | $4.32 – $4.53 | $1.51B | $1.48B – $1.54B | 2 |
